Although stigmata of immune anti-tumor response (i.e., Perforin, CD39, RORγt) could be observed in the CRC patient’s tumor tissue in the present observation, cytotoxicity was not deemed likely to sufficiently imprint longer survival (Seow et al., 2016; Simoni et al., 2018). The gene discussed is PRF1; the disease is neoplasm.